Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000635044 | SCV000756422 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2023-12-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002492968 | SCV002779744 | uncertain significance | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002529832 | SCV003550775 | uncertain significance | Inborn genetic diseases | 2022-04-25 | criteria provided, single submitter | clinical testing | The c.3581G>A (p.R1194Q) alteration is located in exon 17 (coding exon 16) of the CACNA1H gene. This alteration results from a G to A substitution at nucleotide position 3581, causing the arginine (R) at amino acid position 1194 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |